Skip to main content
Clinical Trials/NCT05736341
NCT05736341
Completed
Not Applicable

Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia

Yonsei University1 site in 1 country80 target enrollmentMay 17, 2023

Overview

Phase
Not Applicable
Intervention
Remimazolam besylate
Conditions
Pregnancy
Sponsor
Yonsei University
Enrollment
80
Locations
1
Primary Endpoint
intraoperative nausea and vomiting during sedative period
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Spinal anesthesia is widely accepted as the anesthetic method of choice for Cesarean section. However, high-level blockage or hypotension induced by this technique may induce intraoperative nausea and vomiting (IONV), which is associated with patient discomfort and protrusion of abdominal viscera which may adversely affect patient safety. To prevent IONV, midazolam is frequently administered after delivery, but risk of hypotension and prolonged sedation due to its active metabolite also increases. On the other hand, remimazolam is known to have relatively shorter half-life and less likely induce hypotension when compared to midazolam, yet its effect on IONV has not been thoroughly evaluated. Hence, this study aimed to compare the effects of remimazolam and midazolam in preventing IONV in patients scheduled for elective Cesarean section.

Registry
clinicaltrials.gov
Start Date
May 17, 2023
End Date
January 6, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients (age ≥ 20yrs and ASA Class II or III) who are scheduled for elective Cesarean section

Exclusion Criteria

  • Emergency surgery Patients who are diagnosed preeclampsia or eclampsia, BMI ≥ 40kg/m2, IUP \< 36 weeks Patients with contraindications to spinal anesthesia Patients who do not want sedation during the procedure

Arms & Interventions

Remimazolam

Patient group who receives remimazolam for sedation after delivery

Intervention: Remimazolam besylate

Midazolam

Patient group who receives midazolam for sedation after delivery

Intervention: Midazolam

Outcomes

Primary Outcomes

intraoperative nausea and vomiting during sedative period

Time Frame: at the end of surgery

Incidence of intraoperative nausea, retching, and vomiting will be evaluated 5, 10, 15, 20, 25, 30, and 60 minutes after sedative administration, and at the end of surgery.

Study Sites (1)

Loading locations...

Similar Trials